Katia Bencardino

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda — Italy

Medicine · Health Sciences

31h-index7.8kcitations152works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(82), Cancer Genomics and Diagnostics(45), Lung Cancer Treatments and Mutations(33), Gastric Cancer Management and Outcomes(21), HER2/EGFR in Cancer Research(15)

Publications151 total

A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study
Digestive and Liver Disease·2025
Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial
The Lancet Oncology·2025· 5 cited
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
The Lancet·2025· 5 cited
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies
Drugs·2025· 4 citedOpen Access
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma
Pancreatology·2025
LBA85 Results of a randomized phase III trial of short-course versus long-course pre-operative chemotherapy for stage I-III pancreatic ductal adenocarcinoma (PDAC)
Annals of Oncology·2025
Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study
ESMO Gastrointestinal Oncology·2025Open Access
Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like Features
2025Open Access
44P Rechallenge with anti-HER2 regimens in metastatic colorectal cancer: The retrospective RHEA study
Annals of Oncology·2025· 1 citedOpen Access
82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer
Annals of Oncology·2025Open Access
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology·2025· 9 cited
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
BMC Cancer·2025· 6 citedOpen Access
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review
Cancer Treatment Reviews·2025· 9 citedOpen Access
Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline <scp><i>BRCA</i>1</scp>‐2 Pathogenic Variants
Cancer Medicine·2025· 2 citedOpen Access
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
Diagnostics·2024· 1 citedOpen Access
509O Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): First results of NO-CUT trial
Annals of Oncology·2024· 10 citedOpen Access
THU-486-YI A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events
Journal of Hepatology·2024· 1 cited
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
Clinical Colorectal Cancer·2024· 14 citedOpen Access
Clinicopathological characterisation of <i>MTAP</i> alterations in gastrointestinal cancers
Journal of Clinical Pathology·2024· 11 citedOpen Access
A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events
Digestive and Liver Disease·2024
page 1 of 8Next →

Frequent Co-authors

Salvatore Siena(33), Andrea Sartore‐Bianchi(32), Alessio Amatu(27), Alberto Bardelli(17), Federica Tosi(15), Erica Bonazzina(12), Silvia Ghezzi(11), Silvia Marsoni(11), Emanuele Valtorta(10), Gianluca Mauri(10), Sara Lonardi(9), Laura Palmeri(9), Andrea Cassingena(9), Angelo Vanzulli(9), Silvio Veronese(8), Federica Di Nicolantonio(8), Vittorina Zagonel(8), Giulia Siravegna(7), Cosimo Martino(7), Francesco Leone(7)